JP2017528460A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528460A5
JP2017528460A5 JP2017512975A JP2017512975A JP2017528460A5 JP 2017528460 A5 JP2017528460 A5 JP 2017528460A5 JP 2017512975 A JP2017512975 A JP 2017512975A JP 2017512975 A JP2017512975 A JP 2017512975A JP 2017528460 A5 JP2017528460 A5 JP 2017528460A5
Authority
JP
Japan
Prior art keywords
cancer
cell
tumor
lymphoma
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017512975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528460A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049231 external-priority patent/WO2016040511A1/en
Publication of JP2017528460A publication Critical patent/JP2017528460A/ja
Publication of JP2017528460A5 publication Critical patent/JP2017528460A5/ja
Pending legal-status Critical Current

Links

JP2017512975A 2014-09-10 2015-09-09 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド Pending JP2017528460A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048760P 2014-09-10 2014-09-10
US62/048,760 2014-09-10
PCT/US2015/049231 WO2016040511A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamides as irreversible smyd inhibitors

Publications (2)

Publication Number Publication Date
JP2017528460A JP2017528460A (ja) 2017-09-28
JP2017528460A5 true JP2017528460A5 (enExample) 2018-10-25

Family

ID=55459533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017512975A Pending JP2017528460A (ja) 2014-09-10 2015-09-09 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド

Country Status (6)

Country Link
US (2) US10179773B2 (enExample)
EP (1) EP3193606B1 (enExample)
JP (1) JP2017528460A (enExample)
AU (1) AU2015315180A1 (enExample)
CA (1) CA2960279A1 (enExample)
WO (1) WO2016040511A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
WO2016040511A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
CN114246851B (zh) * 2021-11-09 2024-01-26 澳门科技大学 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途
CN115998869B (zh) * 2022-09-23 2025-08-05 华中科技大学同济医学院附属同济医院 组蛋白甲基转移酶smyd2在制备防治血管损伤后内膜新生导致再狭窄的药物中的应用
IT202200021138A1 (it) * 2022-10-13 2024-04-13 Istituto Di Ricovero E Cura A Carattere Scient Saverio De Bellis Formulati farmaceutici con attività inibente le metiltrasferasi istoniche per il trattamento di patologie neoplastiche
CN116211867A (zh) * 2022-12-30 2023-06-06 复旦大学附属肿瘤医院 Az505和恩杂鲁胺在制备治疗前列腺癌药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518368A (ja) * 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのn−ヘテロシクリル置換アミノチアゾール誘導体
CN1528745A (zh) * 2003-10-21 2004-09-15 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
WO2008137834A2 (en) 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
EP3193609A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
JP2017527577A (ja) 2014-09-10 2017-09-21 エピザイム,インコーポレイティド 置換ピロリジン化合物
WO2016040511A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds

Similar Documents

Publication Publication Date Title
RU2018138735A (ru) Деструкторы белка mdm2
JP2016514695A5 (enExample)
JP2017528464A5 (enExample)
JP2017538659A5 (enExample)
JP2017526706A5 (enExample)
JP2017527577A5 (enExample)
JP2019514950A5 (enExample)
CY1121661T1 (el) Παραγωγα πυριδονης ως αναστολεις της αναδιαταγμενης κατα τη διαμολυνση (ret) κινασης
JP2017527576A5 (enExample)
Kamdje et al. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment
DOP2017000067A (es) Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
Bellaye et al. Heat shock proteins in fibrosis and wound healing: good or evil?
JP2017528461A5 (enExample)
JP2009515851A5 (enExample)
IL272697B1 (en) A polymorphic form of tg02
Park et al. Olmutinib (BI 1482694; HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D
JP2015533796A5 (enExample)
Sharma et al. ErbBs in lung cancer
NZ595602A (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
JP2019507143A5 (enExample)
RU2016118008A (ru) Применение ингибиторов бромодомена свр/ер300 для иммунотерапии рака
EA201492004A1 (ru) Органические композиции для лечения kras-ассоциированных заболеваний
EA200901538A1 (ru) Замещенные пирролопиридины и пиразолопиридины в качестве модуляторов киназ
FI4053128T3 (fi) 5-(2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)-3-(1h-pyratsol-1-yyli)pyratsolo[1,5-a]pyrimidiinijohdannaisia ja niihin liittyviä yhdisteitä trk-kinaasinhibiittoreina syövän hoitoon
JP2024506612A5 (enExample)